MOFSL has reiterated a Sell rating on Cyient Ltd, with SoTP-based target price of ₹1,020, implying an 11 per cent downside from the previous close of ₹1,144.
Cyient reported Profit After Tax (PAT) of ₹163 crore, a Y-o-Y growth of 30 per cent, and revenue of ₹1,393 crore, marking a Q-o-Q decline of 0.3 per cent and Y-o-Y growth of 3.6 per cent.
Metropolis Healthcare, Alembic Pharma and Tejas Networks are the other 3 stocks to witness a 'Death Cross' on the chart in recent days; technically this is a negative development for these stocks.
Chart shows that stocks like Cyient, Rajesh Exports, Mahindra Life, SW Solar and Gujarat Pipavav have tumbled up to 81 per cent from the highs in around last two years; Bias remains negative.
Cyient's profit fell 31.7 per cent quarter-on-quarter (Q-o-Q) to Rs 122.3 crore in Q3FY25, from 179.1 crore in the September quarter of financial year 2025 (Q2FY25)
The acquisition is part of the company's strategic expansion of its semiconductor business. In July last year, the company announced the establishment of a fully owned subsidiary
The rise in the Cyient share price came after the company announced that it has incorporated Cyient Semiconductors Private Limited as a wholly owned subsidiary of the company.
The uptick in stock price came after the company announced the strategic expansion of its semiconductor business with the establishment of a fully owned subsidiary
IT engineering cos provide product engineering services in auto, aerospace, medical device, and utility sectors. On the other hand, software engineering firms are mostly engaged in software products
